- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Stemline Therapeutics Manipulating Patient Boards to Promote Company Stock
The clinical stage biopharmaceutical company Stemline Therapeutics has been caught editing patient anecdotes on message boards managed by the Leukemia & Lymphoma Society in an effort to make its investigational cancer therapy, SL-401, appear better than it is to promote the company's stock.
SL-401 is being indicated for the treatment of refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN), a very rare form of cancer that attacks certain immune cells in the blood and bone marrow.
Manipulating patient anecdotes
Stemline has not yet received permission from the FDA to conduct its own clinical trials, so it has had to rely on anecdotal patient information to do its promoting. Unfortunately, the anecdotal patient information as it has been appearing on message boards isn't quite what the company wants to hear, so Stemline has taken it upon itself to make the changes necessary to put a shimmer and shine on the compound.
Adam Feuerstein tells the whole ugly story at The Street in Stemline Cribs Cancer Patient Message Boards to Promote Stock.